Cyclerion Therapeutics In... (CYCN)
3.07
0.15 (5.14%)
At close: Jan 15, 2025, 11:31 AM
undefined% (undefined)
| Bid | 3.04 |
| Market Cap | 8.32M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.08 |
| PE Ratio (ttm) | -1.48 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 3.11 |
| Volume | 27,929 |
| Avg. Volume (20D) | 3,236,859 |
| Open | 3.00 |
| Previous Close | 2.92 |
| Day's Range | 2.91 - 3.07 |
| 52-Week Range | 1.27 - 9.47 |
| Beta | undefined |
About CYCN
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's dis...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 18, 2019
Employees 1
Stock Exchange NASDAQ
Ticker Symbol CYCN
Website https://www.cyclerion.com
